Study of CPI-006 as Immunotherapy for Hospitalized COVID-19 Patients

Inclusion Criteria: * Nasal swab test positive by reverse transcriptase PCR for SARS CoV-2 within past 7 days, and onset of COVID-19 symptoms no more than 10 days prior to the positive test * Hospitalized and have stable mild to moderate symptoms of COVID-19 * Blood oxygen saturation of a minimum of 92% on either no oxygen or up to 5L/min supplemental oxygen * Patients with cancer must be in remission or have stable, controlled disease and may be actively receiving drugs or biologics not deemed by the investigator to likely affect immune response. * Women must not be of child bearing potential or agree to use contraceptive guidance for 6 weeks Exclusion Criteria: * Patients receiving previous invasive mechanical ventilation or non-invasive ventilation (CPAP, BiPAP) for COVID-19 illness * Patients hospitalized \>7 days prior to receiving study intervention * Other diseases or conditions that are not controlled * On drugs or biologics that are immunosuppressive, cytotoxic or immunomodulatory * Patients with autoimmune disease must be controlled on non immunosuppressive or immune modifying agents * Have received cytotoxic, immunosuppressive or immunomodulatory agents within past 3 months (other than for treatment of COVID-19). * Patients receiving experimental therapies that are immunosuppressive * Patients receiving non-immuno-suppressive experimental therapies within 7 days prior to receiving CPI-006 * Patients receiving convalescent plasma within 24 hours prior to receiving CPI-006 * Patients receiving experimental anti-SARS CoV-2 monoclonal antibodies within past 30 days